Polymorphism of Janus Kinase 1 and 2 (JAK 1&2) in Patients With Alopecia Areata
NCT05861401 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2023-05-16
Summary
Introduction Alopecia areata (AA) is a complex inflammatory disease characterized by cellular infiltration of T- lymphocytes targeting hair follicles, disrupting the anagen phase, with spontaneous remission, recurrence, and exacerbation, making it very unpredictable and emotionally disturbing . It affects nearly 1-2% of the general population with a lifetime risk of 2%, The onset of AA might be at any age; however, most patients develop the disease before 40 years of age . Early-onset AA (a mean age of onset at 5-10 years) predominantly presents as a more severe subtype, such as alopecia universalis . Alopecia areata presents clinically as a non-scarring patchy hair loss primarily on the scalp, and/or other hairy areas and may progress to total scalp hair loss (alopecia totalis, AT ) or complete body hair loss (alopecia universalis, AU ) . Approximately 5- 10% of AA patients will progress into AT/AU . The course of AA varies greatly, the strongest predictors of a poor prognosis include AT, AU, or ophiasis pattern hair loss, as well as earlier age of onset . Severe and recurrent AA disturbs quality of life of patients and may also lead to depression, changed self-image,and interferes with social activities . Currently, the hypotheses for AA development mostly focus on the collapse of immune privilege properties of the hair follicles(HFs) and the nature of self-antigen presentation (follicular antigens) that result in the induction and subsequent attack of activated lymphocytes . Activation of the lymphocytes mainly CD8+NKG2D+induces release of severalTh1 cytokines; interleukin (IL)-1α , IL-1β , and tumor necrosis factor (TNF) alpha, capable of inhibiting (HF) growth with early termination of anagen . AA is a polygenic disorder in which several major genes dictate susceptibility to disease, up to 28% of patients report at least one affected family member, monozygotic twins have exhibited similar times of onset and patterns of hair loss.
Genes loci for Human leucocyte antigens (HLA)DRB1\* 1104 and DQB1\* 03 are detected in patients with AA. The Janus kinases (JAKs) and signal transducer and activator of transcription (STAT); (JAK/STAT) pathway play an important role in inflammatory processes as they are involved in signaling for over 50 cytokines and growth factors. The JAK/STAT pathway transduces multiple extracellular signals involved in cell proliferation, differentiation, migration, and apoptosis .
The JAK family is constituted by four types of cytoplasmic tyrosine kinases:
JAK1, JAK2, JAK3, and TYK2 . STAT, of which there are seven different subtypes (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6) (17), is the other fundamental component of the cascade . After being phosphorylated by JAK, STAT translocates to the nucleus to induce the transcription of specific genes. Alterations in the JAK/STAT pathway have been related to the pathophysiology of atopic dermatitis (AD), vitiligo, and AA.
Conditions
Interventions
- GENETIC
-
Janus Kinase 1 and 2
Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
Sponsors & Collaborators
-
Sohag University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SCREENING
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 4 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-30
- Primary Completion
- 2024-05-31
- Completion
- 2024-05-31
Countries
- Egypt
Study Locations
More Related Trials
-
Quantification of the Socio-economic Multifacet Burden of Alopecia Areata and Identification of the Associated Factors
NCT05588310 ·Status: UNKNOWN
-
PAI-1 Expression in Non-scarring Hair Loss
NCT02548689 ·Status: TERMINATED
-
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
NCT05255237 ·Status: COMPLETED ·Phase: PHASE3
-
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
NCT02312882 ·Status: COMPLETED ·Phase: NA
-
Natural History and Pathogenesis of Alopecia in Children and Adults
NCT05502796 ·Status: COMPLETED
-
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
NCT05051761 ·Status: COMPLETED ·Phase: PHASE3
-
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
NCT02974868 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacogenomic Study of Androgenetic Alopecia
NCT01227031 ·Status: UNKNOWN
-
Efalizumab in the Treatment of Alopecia, Phase II
NCT00746980 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of JNJ-64304500 in Participants With Alopecia Areata
NCT04740970 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
NCT04034134 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
NCT05556265 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Secukinumab for the Treatment of Alopecia Areata
NCT02599129 ·Status: TERMINATED ·Phase: PHASE2
-
Androgenetic Alopecia in Fabry Disease
NCT01295008 ·Status: COMPLETED
-
New Treatment of Alopecia Areata
NCT05594316 ·Status: COMPLETED ·Phase: NA
-
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia
NCT00691769 ·Status: COMPLETED
-
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata
NCT01950780 ·Status: COMPLETED ·Phase: PHASE2
-
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
NCT05098600 ·Status: COMPLETED
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
NCT05398809 ·Status: RECRUITING ·Phase: PHASE2
-
Ocular Finding in Alopecia Areata
NCT03155958 ·Status: UNKNOWN
-
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
NCT03359356 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata
NCT01840046 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
NCT05589610 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
NCT04011748 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
NCT06278402 ·Status: COMPLETED ·Phase: PHASE3